7 completed, 5 terminated, 1 withdrawn. 9 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 2, Withdrawn 1 |
| Phase 1 | 7 | Completed 4, Terminated 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Advaxis, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer ADXS-503, Pembrolizumab - Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | Advaxis, Inc. | 24 | 2019-02-12 | 2024-06-04 |
| A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy ADXS11-001, Pemetrexed - Carcinoma, Non-Small-Cell Lung | Phase 2 | Withdrawn | Advaxis, Inc. | 2018-12-01 | 2023-12-19 | |
| A Study of ADXS-NEO Expressing Personalized Tumor Antigens ADXS-NEO, Pembrolizumab - Colon Cancer Metastatic, Head and Neck Cancer Metastatic | Phase 1 | Terminated | Advaxis, Inc. | 13 | 2018-03-28 | 2023-02-24 |
| A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal Axalimogene filolisbac - Anal Cancer, Rectal Cancer | Phase 2 | Completed | Advaxis, Inc. | 36 | 2016-06-02 | 2023-03-20 |
| Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer ADXS11-001, Placebo - High Risk Cervical Cancer, Advanced Cervical Cancer | Phase 3 | Terminated | Advaxis, Inc. | 110 | 2015-12-15 | 2023-03-14 |
| Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors ADXS31-164 - HER2 Expressing Solid Tumors | Phase 1 / Phase 2 | Completed | Advaxis, Inc. | 12 | 2015-09-01 | 2020-07-16 |
| ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC) ADXS31-142, Pembrolizumab - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | Advaxis, Inc. | 50 | 2015-06-04 | 2024-04-02 |
| A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer ADXS11-001, MEDI4736 - Cervical Cancer, Cancer | Phase 1 / Phase 2 | Terminated | Advaxis, Inc. | 75 | 2015-04-01 | 2023-03-20 |
| Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Axalimogene filolisbac - Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer | Phase 1 | Completed | Advaxis, Inc. | 12 | 2015-03-04 | 2024-05-20 |
| ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer ADXS11-001 (ADXS-HPV) - Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Completed | Andrew Sikora | 15 | 2013-12-01 | 2022-09-22 |
| Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer ADXS11-001 - HPV-16 +ve Oropharyngeal Carcinoma | Phase 1 | Terminated | University of Liverpool | 2 | 2012-02-01 | 2016-05-18 |
| Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001, Laboratory Biomarker Analysis - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 54 | 2011-05-23 | 2020-09-11 |
| An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ ADXS11-001 (Lm-LLO-E7), Placebo Control - Cervical Intraepithelial Neoplasia | Phase 2 | Terminated | Advaxis, Inc. | 81 | 2010-04-01 | 2016-07-27 |
Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Squamous Cell (3) · Neoplasms (3) · Uterine Cervical Neoplasms (3) · Head and Neck Neoplasms (2) · Adenocarcinoma (1) · Anus Neoplasms (1) · Carcinoma (1) · Carcinoma, Adenosquamous (1) · Carcinoma, Small Cell (1) · Carcinoma, Transitional Cell (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Melanoma (1) · Neoplasms by Histologic Type (1)
pembrolizumab (3) · A 503 (1) · Pemetrexed (1) · durvalumab (1)
United States (11) · Argentina (1) · Brazil (1) · Canada (1) · Chile (1) · Malaysia (1) · Mexico (1) · Poland (1) · Russia (1) · Serbia (1) · South Korea (1) · Spain (1) · Taiwan (1) · Ukraine (1) · United Kingdom (1)
Andrew G Sikora, MD PhD (1) · Brett Miles, MD (1) · Surya Vangala (1) · Terence Jones, BSc,FRCS,MD (1) · Warner K Huh (1)
PMID 32341753, PMID 32641240, PMID 35373299, PMID 36220750
2015 (2), U10CA027469 (1), U10CA180830 (1), U10CA180868 (1)